Ann: Change in substantial holding, page-158

My view is the maximum return for shareholders will be achieved once (if) we have Phase II data showing Bisantrene is an inhibitor of FTO in humans and this inhibition is safe and effective at treating multiple cancers. It will take us sometime to get this data and any TO before that point will not maximise returns for the shareholders.

My job as a director is to look after the interest of all shareholders. If I think we can best do this be remaining "under the radar” until the time is right it is my duty to do so. Of course if the shareholders all disagree with me they can choose to remove me from the board and choose someone else who does what they want.